Future studies using centrally confirmed standardized Ki-67 assays which test Ki-67 expression at multiple cutoff points, with assessment of outcomes, are critical in order for Ki-67 to gain international guideline consensus and acceptance as to its prognostic and predictive clinical utility in the care and treatment of breast cancer patients. The gene discussed is MKI67; the disease is breast carcinoma.